Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Monitoring Spinal Anesthesia Block Level Using Segmental Near-Infrared Spectroscopy

8 novembre 2026 aggiornato da: mevlüt aydın

Objective Assessment of Sensory Block Level During Spinal Anesthesia Using Segmental Near-Infrared Spectroscopy: A Prospective Observational Study

Spinal anesthesia is widely used for surgical procedures involving the lower body. Accurate determination of sensory block height is important for ensuring adequate anesthesia and patient safety. Sensory block levels are conventionally assessed using clinical tests that depend on patient responses.

Near-infrared spectroscopy (NIRS) is a noninvasive monitoring technique that measures regional tissue oxygen saturation (StO₂). Changes in tissue oxygenation following spinal anesthesia may reflect alterations in regional perfusion associated with sympathetic blockade.

This prospective observational study primarily aims to evaluate whether segmental NIRS measurements at the T10 dermatomal level can objectively identify the achievement of a sensory block reaching T10 or higher, a clinically relevant threshold for selected surgical procedures.

As a secondary objective, NIRS measurements at the T4 level will be evaluated to investigate whether changes in regional tissue oxygenation reflect further cephalad spread of spinal anesthesia.

Regional tissue oxygen saturation will be monitored at T10 and T4 before and after spinal anesthesia. NIRS-derived parameters will be compared with clinically determined sensory block levels.

The study will also investigate relationships between segmental NIRS changes, sensory block progression, and hemodynamic alterations.

The findings may contribute to the development of an objective, noninvasive method for monitoring the extent of spinal anesthesia.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This single-center, prospective observational study aims to evaluate the utility of segmental near-infrared spectroscopy (NIRS) for objectively assessing sensory block height during spinal anesthesia.

Study Objectives

The primary objective is to evaluate the diagnostic performance of changes in regional tissue oxygen saturation (StO₂) at the T10 dermatomal level for detecting sensory blockade reaching T10 or higher.

The secondary objective is to investigate whether NIRS measurements at the T4 dermatome provide additional information regarding the cephalad spread of spinal anesthesia.

Spinal Anesthesia Management and Intrathecal Drug Administration

All patients will undergo routine preoperative anesthetic assessment and standard monitoring, including electrocardiography, noninvasive blood pressure measurement, and peripheral oxygen saturation monitoring.

Spinal anesthesia will be performed under aseptic conditions, typically at the L3-L4 or L4-L5 intervertebral space, with the patient in either the sitting or lateral decubitus position.

Intrathecal anesthesia will generally be performed using 0.5% hyperbaric bupivacaine. Based on commonly used clinical dosing regimens, an intrathecal dose of approximately 10-15 mg (2-3 mL) is anticipated, depending on the surgical procedure, patient characteristics, and required sensory block height.

The exact intrathecal local anesthetic dose will be determined by the attending anesthesiologist according to routine clinical practice and individual patient requirements. No specific drug dose will be assigned or randomized by the research protocol.

If intrathecal adjuvants are administered as part of routine care, their type and dose will be recorded.

The following spinal anesthesia-related variables will be documented:

  • Type, concentration, and total dose of intrathecal local anesthetic.
  • Type and dose of any intrathecal adjuvant.
  • Spinal puncture level and needle characteristics.
  • Patient position during spinal injection.
  • Time of intrathecal drug administration.
  • Perioperative fluid administration and sedative medications.

These variables will be considered in the analysis because intrathecal drug dose, solution baricity, and patient positioning may influence sensory block spread and associated hemodynamic changes.

Segmental NIRS Monitoring and Sensory Block Assessment

Regional tissue oxygen saturation will be monitored using NIRS sensors positioned at predefined anatomical sites corresponding to the T10 and T4 dermatomal levels.

Baseline measurements will be obtained before spinal anesthesia. Subsequent NIRS measurements and clinical assessments will be recorded immediately after intrathecal injection (0 minutes) and at 5, 10, 15, 20, and 30 minutes.

Sensory block height will be assessed using a standardized clinical dermatomal testing method. Motor blockade will be evaluated using the Bromage scale.

Mean arterial pressure, heart rate, peripheral oxygen saturation, and relevant intraoperative events will be recorded.

Primary Outcome: T10 Sensory Block Assessment

Changes in tissue oxygen saturation from baseline at the T10 level (ΔStO₂-T10) will be analyzed in relation to clinically confirmed sensory blockade reaching T10 or higher.

Receiver operating characteristic (ROC) curve analysis will be used to evaluate the diagnostic discrimination of T10-derived NIRS parameters.

Secondary Outcome: T4 Sensory Block Assessment

Changes in tissue oxygen saturation at the T4 level (ΔStO₂-T4) will be analyzed to determine whether they reflect further cephalad progression of sensory blockade.

Intersegmental differences between T10 and T4 measurements will also be explored as potential indicators of block spread.

Hemodynamic Assessment and Statistical Analysis

Associations between NIRS-derived parameters, sensory block progression, and hemodynamic changes will be evaluated.

The occurrence of hypotension, vasopressor requirements, and other relevant clinical events will be documented.

Statistical analyses will account for repeated measurements within participants where appropriate. Potential confounding factors, including intrathecal local anesthetic dose, use of adjuvants, patient positioning, and surgical characteristics, will be considered.

Clinical Management

This study is observational and will not alter routine anesthetic management.

Spinal anesthesia techniques, intrathecal drug selection, dose adjustments, and treatment of perioperative complications will remain under the responsibility of the attending anesthesiologist.

NIRS measurements collected for research purposes will not be used to guide clinical treatment decisions.

Tipo di studio

Osservativo

Iscrizione (Stimato)

80

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Istanbul
      • Istanbul, Istanbul, Turchia (Türkiye), 34212
        • Bagcilar Training and Research Hospital
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Metodo di campionamento

Campione di probabilità

Popolazione di studio

Adult female patients aged 18-75 years with ASA physical status I-III undergoing elective non-obstetric gynecological surgery under spinal anesthesia at Bagcilar Training and Research Hospital, Istanbul, Turkey. Eligible patients will be prospectively enrolled, and segmental NIRS measurements at T10 and T4 will be compared with clinically assessed sensory block levels.

Descrizione

Inclusion Criteria:

  • Female patients aged 18-75 years.
  • ASA physical status I-III.
  • Scheduled for elective non-obstetric gynecological surgery under spinal anesthesia.
  • Provision of written informed consent.

Exclusion Criteria:

  • Contraindications to spinal anesthesia.
  • Neurological disorders or chronic pain syndromes affecting sensory block assessment.
  • Skin lesions, anatomical abnormalities, or BMI >40 kg/m² interfering with reliable NIRS monitoring.
  • Severe hemodynamic instability or continuous vasopressor requirement before spinal anesthesia.
  • Emergency surgery or planned general anesthesia.
  • Inability to cooperate with sensory block assessment.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Spinal Anesthesia Cohort

Patients undergoing surgery under spinal anesthesia will be prospectively enrolled in a single observational cohort.

Regional tissue oxygen saturation (StO₂) will be monitored using segmental near-infrared spectroscopy (NIRS) at the T10 and T4 dermatomal levels.

The primary objective is to evaluate the diagnostic performance of T10 NIRS measurements for identifying clinically confirmed sensory blockade reaching T10 or higher.

T4 NIRS measurements will be evaluated as a secondary indicator of further cephalad spread of sensory blockade.

Spinal anesthesia will be performed according to routine clinical practice, without protocol-assigned intrathecal drug doses. NIRS monitoring will not influence clinical management.

Segmental near-infrared spectroscopy (NIRS) will be used to noninvasively measure regional tissue oxygen saturation (StO₂) at the T10 and T4 dermatomal levels in patients undergoing spinal anesthesia.

Measurements will be obtained before spinal anesthesia and at 0, 5, 10, 15, 20, and 30 minutes following intrathecal injection.

Changes in T10 tissue oxygen saturation will be evaluated for their ability to identify sensory blockade reaching T10 or higher, while T4 measurements will be assessed for their association with further cephalad block spread.

NIRS-derived parameters will be compared with standard clinical sensory block assessments. NIRS measurements will be collected for observational research purposes and will not guide anesthetic management.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Diagnostic Accuracy of T10 NIRS at 5 Minutes After Spinal Anesthesia
Lasso di tempo: Baseline to 5 minutes after intrathecal injection.

The diagnostic performance of the change in regional tissue oxygen saturation at the T10 dermatome (ΔStO₂-T10) from baseline to 5 minutes after intrathecal injection will be evaluated for detecting clinically confirmed sensory blockade reaching T10 or higher at the 5-minute assessment.

Diagnostic accuracy will be quantified using the area under the receiver operating characteristic curve (ROC-AUC), with a 95% confidence interval.

Baseline to 5 minutes after intrathecal injection.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Temporal Changes in Regional Tissue Oxygen Saturation at T10 and T4
Lasso di tempo: Baseline and 0, 5, 10, 15, 20, and 30 minutes after intrathecal injection.

Regional tissue oxygen saturation (StO₂) will be recorded at the T10 and T4 dermatomal levels before and after spinal anesthesia. Absolute changes from baseline (ΔStO₂, expressed in percentage points) will be calculated at each measurement time. Temporal changes in ΔStO₂ at both sites will be evaluated using longitudinal statistical methods accounting for within-patient correlations. Intersegmental differences between T10 and T4 responses will also be explored.

Baseline and 0, 5, 10, 15, 20, and 30 minutes after intrathecal injection.
Association Between T4 NIRS Changes and Cephalad Sensory Block Height
Lasso di tempo: Baseline and 0, 5, 10, 15, 20, and 30 minutes after intrathecal injection.

Changes from baseline in regional tissue oxygen saturation at the T4 dermatome (ΔStO₂-T4, expressed in percentage points) will be assessed in relation to clinically determined sensory block height at corresponding measurement times. The association will be evaluated using statistical methods accounting for repeated observations within patients. The diagnostic performance of T4 NIRS changes for detecting sensory blockade at or above T4 will be explored if sufficient patients reach this level.

Baseline and 0, 5, 10, 15, 20, and 30 minutes after intrathecal injection.
Proportion of Patients Developing Hypotension Following Spinal Anesthesia
Lasso di tempo: From intrathecal injection until completion of surgery.

The proportion of patients experiencing at least one episode of hypotension after spinal anesthesia will be recorded. Hypotension will be defined as mean arterial pressure below 65 mmHg or a decrease of more than 20% from baseline. The incidence of hypotension will be expressed as the number and percentage of affected patients. Associations with sensory block height and NIRS-derived parameters will be explored.

From intrathecal injection until completion of surgery.

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Predictive Performance of 5-Minute T10 NIRS Changes for Sensory Block Achievement at 10 Minutes
Lasso di tempo: From 5 to 10 minutes after intrathecal injection.

Among patients who have not achieved sensory blockade at or above T10 at 5 minutes after intrathecal injection, the predictive performance of ΔStO₂-T10 measured at 5 minutes will be evaluated for identifying patients who achieve clinically confirmed T10 sensory blockade by 10 minutes. Predictive discrimination will be explored using ROC-AUC with 95% confidence intervals, where estimable. The additional predictive value beyond the clinically assessed sensory block level at 5 minutes may be investigated if sample size permits.

From 5 to 10 minutes after intrathecal injection.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 novembre 2026

Completamento primario (Stimato)

30 novembre 2026

Completamento dello studio (Stimato)

31 dicembre 2026

Date di iscrizione allo studio

Primo inviato

8 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

8 novembre 2026

Primo Inserito (Effettivo)

16 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

8 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • BTRH-MA-NIRS-01

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Descrizione del piano IPD

A final decision regarding the sharing of de-identified individual participant data has not yet been made. Data sharing options will be evaluated in accordance with institutional policies, ethics committee requirements, and applicable data protection regulations.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .